Literature DB >> 19443516

Nitric oxide mechanisms of nebivolol.

Angelo Maffei1, Giuseppe Lembo.   

Abstract

beta-blockers are among the most widely used drugs in the prevention and treatment of cardiovascular disease, although they are associated with increased peripheral resistance. Third-generation beta-blockers avoid this adverse effect by inducing vasodilation through different mechanisms. In particular, nebivolol, a highly selective blocker of beta(1)-adrenergic receptors, is the only beta-blocker known to induce vascular production of nitric oxide, the main endothelial vasodilator. The specific mechanism of nebivolol is particularly relevant in hypertension, where nitric oxide dysfunction occurs. Indeed, nebivolol is able to reverse endothelial dysfunction. Nebivolol induces nitric oxide production via activation of beta(3)-adrenergic receptors, which can explain the good metabolic profile observed after treatment with this drug. Moreover, nebivolol can also stimulate the beta(3)-adrenergic receptor-mediated production of nitric oxide in the heart, and this stimulation can result in a greater protection against heart failure. In conclusion, nebivolol has a unique profile among antihypertensive drugs, adding to a very high selectivity against beta(1) adrenergic receptors, and an agonist action on beta(3) receptors and nitric oxide (NO), which has led to clinically significant improvements in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443516     DOI: 10.1177/1753944709104496

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  10 in total

Review 1.  Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.

Authors:  Abhishek Jaiswal; Astha Chichra; Vinh Q Nguyen; Taraka V Gadiraju; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2016-02

2.  Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation.

Authors:  Juan P Aragón; Marah E Condit; Shashi Bhushan; Benjamin L Predmore; Sandeep S Patel; D Bennett Grinsfelder; Susheel Gundewar; Saurabh Jha; John W Calvert; Lili A Barouch; Madhav Lavu; Harold M Wright; David J Lefer
Journal:  J Am Coll Cardiol       Date:  2011-12-13       Impact factor: 24.094

3.  Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography.

Authors:  Mustafa Yılmaz; Alp Aydınalp; Kaan Okyay; Abdullah Tekin; Uğur Abbas Bal; Nilüfer Bayraktar; Aylin Yıldırır; Haldun Müderrisoğlu
Journal:  Cardiorenal Med       Date:  2015-05-30       Impact factor: 2.041

Review 4.  Vascular effects of antihypertensive drug therapy.

Authors:  Asia Rehman; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 5.  Adrenergic signaling in heart failure and cardiovascular aging.

Authors:  Gaetano Santulli; Guido Iaccarino
Journal:  Maturitas       Date:  2016-03-26       Impact factor: 4.342

6.  Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.

Authors:  Otto Kamp; Marco Metra; Silvia Bugatti; Luca Bettari; Alessandra Dei Cas; Natalia Petrini; Livio Dei Cas
Journal:  Drugs       Date:  2010       Impact factor: 9.546

Review 7.  Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.

Authors:  Thomas D Giles; John R Cockcroft; Bertram Pitt; Abhijeet Jakate; Harold M Wright
Journal:  J Hypertens       Date:  2017-09       Impact factor: 4.844

Review 8.  Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.

Authors:  A Coats; S Jain
Journal:  J Hum Hypertens       Date:  2017-03-02       Impact factor: 3.012

Review 9.  Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases.

Authors:  Maurizio Forte; Valeria Conti; Antonio Damato; Mariateresa Ambrosio; Annibale A Puca; Sebastiano Sciarretta; Giacomo Frati; Carmine Vecchione; Albino Carrizzo
Journal:  Oxid Med Cell Longev       Date:  2016-08-29       Impact factor: 6.543

Review 10.  Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.

Authors:  Waleed AlHabeeb; Sanaa Mrabeti; Ahmed Adel Ibrahim Abdelsalam
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-09       Impact factor: 3.947

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.